Standardizing flow cytometric assays during cell manufacturing

Cell & Gene Therapy Insights 2022; 8(10), 1213

DOI: 10.18609/cgti.2022.179

Published: 3 November 2022
FastFacts
Annika Graband


Watch the video or read the poster to learn how to minimize variation in flow cytometric assays during cell manufacturing with: 

  • Dry recombinant antibody technology 
  • Fully automated data acquisition and analysis 
  • Robust protocols and technical support

Annika Graband is Miltenyi Biotec’s Product Manager responsible for the cell and gene therapy reagents portfolio, including CAR detection reagents and StainExpress™ dry antibody cocktails. During the past year, she has been working together with R&D to advance the development of tools that enable highly reliable and standardized cell and gene therapy analytics. Annika received her PhD from the University of Cologne.